Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Myeloproliferative Neoplasms
NCT03065400Phase 2Completed
- Sponsor
- John Mascarenhas
- Start
- Jun 2017
- Primary completion
- May 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Myeloproliferative Neoplasm (MPN), myelofibrosis (MF), sponsored by John Mascarenhas. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
Myeloproliferative Neoplasm (MPN)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03065400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065400.